OP16 Postoperative endoscopic recurrence after ileocecal resection for Crohn’s disease with Kono-S or side-to-side functional end anastomosis:12-18 months follow-up results from a Multicenter Prospective Randomized Trial

作者：Koiana Trencheva, P. Kienle, Gaetano Luglio, A. D’Hoore, Antonino Spinelli, Sven Flemming, Stefano Scaringi, S Malinka, Paul J. Christos, F Tropeano, Gabriele Bislenghi, Fabrizio Michelassi · 发表于：Journal of Crohn s and Colitis · 年份：2025 · DOI：10.1093/ecco-jcc/jjae190.0016 · 被引用次数：5 · 研究领域：Inflammatory Bowel Disease、Gastric Cancer Management and Outcomes、Colorectal Cancer Surgical Treatments

Abstract Background Previous studies have suggested that a novel anastomosis (Kono-S) is associated with lower endoscopic and surgical recurrence rates after ileocecal resection for Crohn’s disease (CD)[1-3]. This study aims to compare the endoscopic recurrence between the Kono-S and side-to-side functional end anastomosis at 12-18 months after ileocecal resection for CD. Methods Prospective randomized trial conducted at 8 international centers. Patients undergoing ileocecal resection were randomized to a Kono-S(Group 1) or a side-to-side functional end (Group 2) anastomosis and were discharged on no biologicals. Exclusion criteria included age (<18), pregnancy, recurrent or multisite CD, and need of postoperative treatment with biologicals. Data were collected prior to and during surgery, daily after surgery until discharge, at 30 days post-op, and during colonoscopy at 12-18 months(m). Biologic therapy was allowed after the first colonoscopy at 3-6 m. Participating surgeons were instructed in the Kono-S technique through videos. Disease clinical activity was measured by the Harvey-Bradshaw Index (HBI). Endoscopic remission/recurrence was graded with the modified Rutgeerts score, and all sites used the same endoscopic evaluation protocol (Image1). Endoscopic remission was defined as a Rutgeerts score of 0,1 or 2a, and a Rutgeerts score of 2b or higher was considered a recurrence. All study sites had Institutional Review Board approval, ClinicalTrial.gov #NCT03256240. ...